Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 1/20 | 0.67 |
| ▸ | CCNE1 | P24864 | 17/20 | 0.64 |
| ▸ | CDK2 | P24941 | 17/20 | 0.64 |
| ▸ | CCND1 | P24385 | 13/20 | 0.64 |
| ▸ | CDK6 | Q00534 | 13/20 | 0.64 |
| ▸ | CDK4 | P11802 | 10/20 | 0.64 |
| ▸ | CDK1 | P06493 | 7/20 | 0.64 |
| ▸ | CCNB1 | P14635 | 7/20 | 0.64 |
| ▸ | CCND3 | P30281 | 7/20 | 0.64 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.59 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.56 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.53 |
| ▸ | CDK9 | P50750 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22901105 | 0.84 | CCNE1 (0.65) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL29631651 | 0.84 | CCNE1 (0.65) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL26941950 | 0.84 | CDK2 (0.65) | ULK1CCNE1CDK2CCND1CDK6 | |
| SCHEMBL26941973 | 0.83 | CCNE1 (0.65) | ULK1CCNE1CDK2CCND1CDK6 | |
| SCHEMBL26941919 | 0.83 | CCNE1 (0.62) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL24477774 | 0.82 | CDK2 (0.63) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL30906911 | 0.82 | CCNE1 (0.63) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL27213238 | 0.82 | CCNE1 (0.63) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL24477959 | 0.82 | CDK2 (0.61) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL26943498 | 0.82 | ULK1 (0.57) | ULK1CCNE1CDK2CCND1CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250009745-A1 | CDK INHIBITOR | SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) | 2025-01-09 | — | — | US | disclosed |
| EP-4289835-A1 | CDK INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289835-A1 | CDK INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022166793-A1 | CDK INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250009745-A1 | CDK INHIBITOR | CDK9, CDKL1, CDK6 | ULK1 1250/4885CCNE1 32/4885CDK2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.